Table 1:
Mean patient reported outcomes and investigator assessment scores at baseline and week 12, including change from baseline to week 12
| Measure | Baseline, mean (SD, range) | Week 12, mean (SD) | Change, mean (SD) | t-statistic (for change) | Standardized Response Mean (95% CI) | Difference compared to DLQI (95% CI) † | Difference compared to DLQI-R (95% CI) ‡ |
|---|---|---|---|---|---|---|---|
| PASI | 18.9 (7.1, 10.7–52.4) | 11.2 (10.9) | −7.7 (10.2) | −7.3 | 0.76 (0.56 to 0.97) | 0.14 (−0.02 to 0.31) | 0.18 (0.02 to 0.34) |
| PGA | 3.3 (0.6, 2–5) | 2.1 (1.1) | −1.2 (1.1) | −10.5 | 1.10 (0.89 to 1.30) | −0.19 (−0.39 to 0.01) | −0.15 (−0.35 to 0.05) |
| DLQI | 12.5 (6.1, 2–28) | 6.6 (6.9) | −6.1 (6.7) | −8.7 | 0.91 (0.70 to 1.12) | - | −0.03 (−0.07 to 0.00) |
| DLQI-R | 13.5 (6.3, 2–28) | 6.9 (7.1) | −6.6 (7.0) | −9.1 | 0.94 (0.74 to 1.15) | 0.03 (0.00 to 0.07) | - |
| EQ-5D-3L IV | 0.76 (0.17, 0.17–1.00) | 0.85 (0.17) | 0.08 (0.19) | 4.3 | 0.38 (0.18 to 0.57) | 0.53 (0.33 to 0.73) | 0.57 (0.37 to 0.77) |
| EQ VAS | 58.4 (30.6, 4–100) | 64.4 (31.7) | 5.0 (32.2) | 1.5 | 0.14 (−0.07 to 0.35) | 0.77 (0.49 to 1.04) | 0.80 (0.52 to 1.08) |
PASI: Psoriasis Area Severity Index; PGA: Psoriasis Global Assessment; DLQI: Dermatology Life Quality Index; DLQI-R: Dermatology Life Quality Index-Relevant (DLQI-R); EQ-5D-3L: EuroQol 5-Dimension 3-Level; IV: Index Value; VAS: Visual Analog Scale.
†
larger numbers support DLQI more responsive
‡
larger numbers support DLQI-R more responsive